ERBB2 and lung carcinoma: HER2-directed antibody–drug conjugates (ADC) may be useful, but the indication in HR + /HER2− ABC is for HER2-low (details below), unlike lung cancer where FDA approval is for HER2-mutated non-small cell lung cancer94.